Your browser doesn't support javascript.
loading
Totality of evidence refutes neoplasm risk with fezolinetant.
Neal-Perry, Genevieve; Santoro, Nanette; Cano, Antonio; Nappi, Rossella E; Shapiro, Marla; Ottery, Faith D.
Afiliação
  • Neal-Perry G; Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
  • Santoro N; Department of Obstetrics and Gynecology, School of Medicine, University of Colorado, Aurora, CO, USA.
  • Cano A; Department of Paediatrics, Obstetrics and Gynaecology, University of Valencia, Valencia, Spain.
  • Nappi RE; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Research Center for Reproductive Medicine and Gynecological Endocrinology-Menopause Unit, Fondazione Policlinico IRCCS S Matteo, Pavia, Italy.
  • Shapiro M; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
  • Ottery FD; Astellas Pharma Global Development, Northbrook, IL 60062, USA. Electronic address: faith.ottery@astellas.com.
Lancet ; 403(10440): 1987-1988, 2024 May 18.
Article em En | MEDLINE | ID: mdl-38762322
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiadiazóis / Compostos Heterocíclicos com 2 Anéis / Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiadiazóis / Compostos Heterocíclicos com 2 Anéis / Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article